KI67 Primary Antibody

Item Information
Catalog #Size/ConcentrationPrice
Specification
AliasesKIA; Ki-67; MKI67
ProductOrderK
Clone#8D5
Entrez GenelD4288
FormulationAscitic fluid containing 0.03% sodium azide.
HostMouse
IsotypeIgG1
ImmunogenSynthetic peptide corresponding to aa (CEDLAGFKELFQTPG) of human KI67, conjugated to KLH.
MW358kDa
Shipping InformationThis product will ship in a box containing blue ice at a temperature of 4°C. Learn More
Species ReactivityHuman
Application
ELISA1/10000
IHC_P(Immunohistochemistry)1/200 - 1/1000
WB (Western Blot)1/500 - 1/2000
Sequence
CEDLAGFKELFQTPG
Catalog#: 30100
Inquire
Contact us to order
Images
Western Blot
Figure 1: Western blot analysis using KI67 mouse mAb against Hela (1), MCF-7 (2) and Raji (3) cell lysate.
Figure 1: Western blot analysis using KI67 mouse mAb against Hela (1), MCF-7 (2) and Raji (3) cell lysate.
Immunohistochemical analysis
Figure 2: Immunohistochemical analysis of paraffin-embedded lung cancer (left) and rectal cancer (right) using KI67 mouse mAb with DAB staining.
Figure 2: Immunohistochemical analysis of paraffin-embedded lung cancer (left) and rectal cancer (right) using KI67 mouse mAb with DAB staining.
Product Overview
Description

Ki67, also known as MKI67, it is the prototypic cell cycle related nuclear protein, expressed by proliferating cells in all phases of the active cell cycle (G1, S, G2 and M phase). It is absent in resting (G0) cells. Ki67 antibodies are useful in establishing the cell growing fraction in neoplasms (immunohistochemically quantified by determining the number of Ki67 positive cells among the total number of resting cells = Ki67 index). In neoplastic tissues the prognostic value is comparable to the tritiated thymidine labelling index. The correlation between low Ki67 index and histologically low grade tumours is strong. Ki67 is routinely used as a neuronal marker of cell cycling and proliferation.

References (references)
References (references)1. Folia Histochem Cytobiol. 2007;45(4):357-66.
2. Tumori. 2008 May-Jun;94(3):389-97.